Literature DB >> 8750601

Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria.

G M Knudsen1, S Hasselbalch, P B Toft, E Christensen, O B Paulson, H Lou.   

Abstract

Blood-brain barrier permeability to phenylalanine and leucine in four patients with phenylketonuria and in four volunteers was measured five times by the double-indicator method at increasing plasma concentrations of phenylalanine. Based on the permeability-surface area product (PS) from blood to brain (PS1) and on plasma phenylalanine levels, Vmax and the apparent Km for phenylalanine were determined. Statistically significant relationships between plasma phenylalanine and PS1 were established in three out of four volunteers, the average Vmax value being 46.7 nmol/g per min and the apparent Km 0.328 mmol/L. Owing to saturation of the carrier, such a relationship could not be established in the patients. In phenylketonuria, PS1 for phenylalanine and leucine decreased significantly by 55% and 46%, respectively. Transport from brain back to blood, PS2, decreased significantly and cerebral large neutral amino acid net uptake was generally decreased in patients with phenylketonuria. In conclusion, the transport of L-phenylalanine across the human blood-brain barrier follows Michaelis-Menten kinetics. In phenylketonuria, brain permeability to large neutral amino acids is reduced by about 50% and net uptake appears decreased.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750601     DOI: 10.1007/bf02436753

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

Review 1.  Amino acid analysis utilizing phenylisothiocyanate derivatives.

Authors:  S A Cohen; D J Strydom
Journal:  Anal Biochem       Date:  1988-10       Impact factor: 3.365

2.  Kinetic analysis of blood-brain barrier transport of D-glucose in man: quantitative evaluation in the presence of tracer backflux and capillary heterogeneity.

Authors:  G M Knudsen; K D Pettigrew; O B Paulson; M M Hertz; C S Patlak
Journal:  Microvasc Res       Date:  1990-01       Impact factor: 3.514

Review 3.  Current trends in the estimation of Michaelis-Menten parameters.

Authors:  G L Atkins; I A Nimmo
Journal:  Anal Biochem       Date:  1980-05-01       Impact factor: 3.365

Review 4.  Application of the double-indicator technique for measurement of blood-brain barrier permeability in humans.

Authors:  G M Knudsen
Journal:  Cerebrovasc Brain Metab Rev       Date:  1994

5.  Blood-brain barrier permeability measurements by double-indicator method using intravenous injection.

Authors:  G M Knudsen; K D Pettigrew; C S Patlak; O B Paulson
Journal:  Am J Physiol       Date:  1994-03

6.  Measurement of cerebral blood flow by intravenous xenon-133 technique and a mobile system. Reproducibility using the Obrist model compared to total curve analysis.

Authors:  T Schroeder; P Holstein; N A Lassen; H C Engell
Journal:  Neurol Res       Date:  1986-12       Impact factor: 2.448

7.  Content of phenylalanine, tyrosine and their metabolites in CSF in phenylketonuria.

Authors:  A G Antoshechkin; T V Chentsova; D B Naritsin; G P Railian
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

8.  The transport of tyrosine into the human brain as determined with L-[1-11C]tyrosine and PET.

Authors:  F A Wiesel; G Blomqvist; C Halldin; I Sjögren; L Bjerkenstedt; N Venizelos; L Hagenfeldt
Journal:  J Nucl Med       Date:  1991-11       Impact factor: 10.057

9.  Kinetics of neutral amino acid transport across the blood-brain barrier.

Authors:  Q R Smith; S Momma; M Aoyagi; S I Rapoport
Journal:  J Neurochem       Date:  1987-11       Impact factor: 5.372

10.  The effect of plasma valine, isoleucine and leucine on the control of the flux through tyrosine- and tryptophan-hydroxylase in the brain.

Authors:  F A Hommes; J S Lee
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

View more
  20 in total

Review 1.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

2.  Non-physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAHENU2 mice.

Authors:  Kara R Vogel; Erland Arning; Brandi L Wasek; Teodoro Bottiglieri; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

3.  Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria.

Authors:  M L Smith; W B Hanley; J T Clarke; P Klim; W Schoonheyt; V Austin; D C Lehotay
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

4.  Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

Authors:  J Pietz; R Kreis; A Rupp; E Mayatepek; D Rating; C Boesch; H J Bremer
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

5.  A Multiplatform Metabolomics Approach to Characterize Plasma Levels of Phenylalanine and Tyrosine in Phenylketonuria.

Authors:  H Blasco; C Veyrat-Durebex; M Bertrand; F Patin; F Labarthe; H Henique; P Emond; C R Andres; C Antar; C Landon; L Nadal-Desbarats; F Maillot
Journal:  JIMD Rep       Date:  2016-06-15

Review 6.  Parkinson's disease: is the initial treatment established?

Authors:  J Eric Ahlskog
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

7.  High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2015-11-26       Impact factor: 4.797

8.  Cerebral net exchange of large neutral amino acids after lipopolysaccharide infusion in healthy humans.

Authors:  Ronan Mg Berg; Sarah Taudorf; Damian M Bailey; Carsten Lundby; Fin Stolze Larsen; Bente Klarlund Pedersen; Kirsten Møller
Journal:  Crit Care       Date:  2010-02-11       Impact factor: 9.097

9.  Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria.

Authors:  J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; H E Möller
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

10.  Use of acute hyperphenylalaninemia in rhesus monkeys to examine sensitivity and stability of the L-[1-11C]leucine method for measurement of regional rates of cerebral protein synthesis with PET.

Authors:  Carolyn B Smith; Kathleen C Schmidt; Shrinivas Bishu; Michael A Channing; Jeff Bacon; Thomas V Burlin; Mei Qin; Zhong-Hua Liu; Zengyan Xia; Tianjiang Huang; Bee-Kee Vuong; Peter Herscovitch
Journal:  J Cereb Blood Flow Metab       Date:  2008-04-23       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.